Current reports
Current report No. 3/2021 – Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US
Subject: Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information, time: 4:42 PM Content of the report: Management Board of Celon Pharma S.A. (the “Company”) wishes to announce that on January 18, 2021,Read more »
Current report No. 2/2021 – The National Centre for Research and Development recommended co-funding of the project dedicated to the development of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain
Subject: The National Centre for Research and Development recommended co-funding of the project dedicated to the development of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information, time: 4:27 PM Content of the report: Management BoardRead more »
Current report No. 1/2021 – Positive results of the phase II clinical trial on Celon Pharma’s DPI esketamine in bipolar treatment-resistant depression [03KET2018]
Date prepared: 01/08/2021, 7:23 PM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. Content of the report: In relation to the current report No. 45/2020 regarding the date for the presentation of results of the phase II clinical trial on esketamine-based DPI drug (Falkieri) in bipolar treatment-resistant depression,Read more »